Pioglitazone treatment in Cushing's disease [1]

Journal of Endocrinological Investigation

Volumn 28, Issue 6, 2005, Pages 388-389

  Barbaro, D ^a   Lapi, P ^a   Orsini, P ^a   Pasquini, C ^a   Ciaccio, S ^a  

^a Sezione Endocrinologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; INSULIN SENSITIZING AGENT; PIOGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANTINEOPLASTIC ACTIVITY; CUSHING DISEASE; HISTOLOGY; HUMAN; HYPERTRIGLYCERIDEMIA; LETTER; NEUROSURGERY; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CASE REPORT; COMORBIDITY; DIABETES MELLITUS; FEMALE; HYPERTENSION; NOTE; TREATMENT OUTCOME;

ADRENOCORTICOTROPIC HORMONE; AGED; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; HYDROCORTISONE; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; PITUITARY ACTH HYPERSECRETION; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 23444444735     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03347209     Document Type: Letter

References (5)

1. Cannavò S, Ambrosi B, Chiodini I, et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing's disease. J Endocrinol Invest 2004, 27: RC8-11.
2. Theocharis S, Margeli A, Kouraklis G. Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents. Curr Med Chem Anti-Cancer Agents 2003, 3: 239-51.
3. Heaney AP, Fernando M, Yong WH, Melmed SM. Functional PPAR-γ receptor is a novel therapeutic target for ACTH - secreting pituitary adenomas. Nat Med 2002, 8: 1281-7.
4. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6 - month randomised placebo-controlled dose-response study. Diabetes Care 2000, 23: 1605-11.
5. Ambrosi B, Dall'Asta C, Cannavo S, et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004, 151: 173-8.